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We use a data driven approach on a cleaned adverse drug reaction database to 
determine the reaction severity of several covid-19 drug combinations currently 
under investigation. We further examine their safety for vulnerable populations 
such as individuals 65 years and older. Our key findings include 1. 
hydroxychloroquine/chloroquine are associated with increased adverse drug event 
severity versus other drug combinations already not recommended by NIH 
treatment guidelines, 2. hydroxychloroquine/azithromycin are associated with 
lower adverse drug event severity among older populations, 3. lopinavir/ritonavir 
had lower adverse reaction severity among toddlers and 4. the combination of 
azithromycin, hydroxychloroquine and tocilizumab is safer than its component 
drugs. While our approach does not consider drug efficacy, it can help prioritize 
clinical trials for drug combinations by focusing on those with the lowest reaction 
severity and thus increase potential treatment options for covid-19 patients. 
Keywords: SARS-CoV-2, Adverse Drug Events, FDA FAERS, TylerADE 
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While the SARS-CoV-2 global pandemic brought much attention to the discovery 
of a vaccine, the use of existing medication to reduce respiratory infection and 
alleviate patient symptoms is equally important. So far there has been no safe and 
effective treatment for the virus. Several medicines have received high-profile 
attention such as the anti-malarial drugs hydroxychloroquine/chloroquine which 
shown early evidence of effective prevention (Liu et al., 2020), and further clinical 
studies finding hydroxychloroquine more effective than chloroquine (Fantini et al., 
2020). Hydroxychloroquine has been found useful for suppressing the cytokine 
storm in late stages of infection, but not effective in inhibiting the early onset stages 
(Yao et al., 2020). Interest has also increased for the drug combination of 
hydroxychloroquine/azithromycin after US President Donald Trump tweeted that 
the combination was one of “the biggest game changers in the history of medicine” 
(Trump, 2020). His tweet cited a small French study of 36 patients that had 
encouraging results (Gautret et al., 2020). However, treatment guidelines from the 
National Institutes of Health (NIH) recommended against their use because of 
potential toxicity (National Institutes of Health, 2020).  
NIH further recommended against the use of lopinavir/ritonavir because of negative 
clinical trial data and has recommended against the use of interferons and janus 
kinase inhibitors. Besides insufficient clinical data to either recommend for or 
against hydroxychloroquine/chloroquine, the NIH also lacks clinical data to provide 
a recommendation for or against the use of interleukin inhibitors such as anakinra, 
sarilumab, siltuximab and tocilizumab.  
As of this writing, these four drugs are just entering worldwide clinical trials.  
While it is vitally important to find effective drugs or combinations in the treatment 
of coronavirus, it is also important to do so quickly by filtering out drug 
combinations with the potential for toxicity or harm. 
Adverse Drug Events (ADEs) are a medical problem that can cause a wide variety 
of symptoms including discomfort, pain, permanent injury or even death.  
These reactions could be an allergy, overdose, a medication error, an unexpected 
interaction between drugs or a reaction that exacerbates an existing disease 
(health.gov, 2017). 
In 1969 the US Food and Drug Administration (FDA) created a reporting system to 
collect and disseminate adverse drug event data.  
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This system, the FDA’s Adverse Event Reporting System (FAERS) was created 
with the mission to become a centralized repository for pharmaceutical 
manufacturers to monitor their post-marketed products for evidence of adverse 
medical device and drug-related events. This voluntary system collects reports from 
drug manufacturers, medical professionals and the general public through 
MedWatch Forms FDA 3500A, 3500 and 3500B respectively. MedWatch collects 
patient demographic information, current medications, the disease or diseases being 
treated, symptoms, patient outcome and information about the reporter.  
This information is publicly available1 and between 2004 Quarter 1 and 2018 
Quarter 2, this reporting system contained nearly 135 million records across  
11 million adverse drug events. However, the FDA FAERS system lacks controls 
in terms of data entry. This has led to a dirty data problem for FAERS that prevents 
it from reaching its potential as a pharmacovigilance tool (Veronon et al., 2020). 
Example problems include non-standardized data such as misspelled drug names, 
use of multiple brand names for the same drug, abbreviations, extraneous 
information, excessive punctuation/formatting, mixed capitalizations and non-
descriptive data such as “unknown purposes.” Further, some records contain 
nonsense data such as patient age of 7,200 years, 168,000lbs weight or symptoms 
such as acupuncture, adolescence or adoption. Fortunately these are a minority of 
records, however, even as a minority they pose certain problems if left untreated 
(Veronin et al., 2020). As a result there are several commercial and open-source 
tools that provide cleaning and simple search capabilities of FAERS data.  
However, these systems have drawbacks with respect to the amount of cleaning 
performed and/or the ability to form complex queries. Our motivation is to create a 
pharmacovigilance system, the Tyler Adverse Drug Event System (TylerADE), to 
perform data cleaning and standardization of FAERS data that can be used to 
identify adverse reaction severity scores based on complex SQL queries such as 
combinations of medication, demographic partitioning by age and gender as well 
as adverse reaction symptoms. This system will allow researchers a finer-grained 
analysis of adverse drug event data to uncover potentially unknown drug 
interactions. This research has the potential to improve the efficiency of 
pharmacological research by identifying potentially unknown drug interactions that 
merit further clinical study and improve patient safety.  
The focus of this paper is to use TylerADE on current SARS-CoV-2 drugs under 
consideration by the NIH as a potential tool to identify those drug combinations 
with significant adverse reactions. While this system is not meant to be a 
replacement to existing drug interaction knowledge or clinical studies, we envision 
it as a complimentary tool that researchers can use to fulfill the promise of FAERS. 
 
1 https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm 
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The rest of this paper is structured as follows. Section 2 is the literature review and 
examines the FDA drug approval process, assessing adverse drug event causality, 
FAERS data and research gaps. Section 3 presents our research questions. Section 
4 is the system design and introduces the TylerADE System. Section 5 is the 
experimental design. Section 6 delivers the experimental results and discussion. 
Finally Section 7 provides the study conclusions, limitations and future directions. 
LITERATURE REVIEW 
 
To better understand the impacts of adverse drug events on society, we will explain 
the drug approval process in the United States, examine several pharmacovigilance 
systems that identify post-approval problems, investigate current systems that use 
FAERS data, describe the current state of SARSCoV-2 drugs under investigation 
and finish with a discourse on the research gaps found within the literature. 
FDA Drug Approval Process 
 
In the United States, the Center for Drug Evaluation and Research (CDER), a 
division of the FDA, is responsible for ensuring the safety of all prescription and 
over-the-counter (OTC) drugs. Although CDER does not test the drugs themselves, 
they rely on testing data from both the manufacturers and the Office of Testing and 
Research to determine if the drug’s health benefits outweigh the risks. 
Before a new drug comes to the market, pharmaceutical manufacturers will submit 
a new drug application along with evidence that it is safe and effective. CDER then 
reviews the data and if the benefits outweigh the risks, the manufacturer will then 
be invited to submit an investigational new drug application. After a typical 30 day 
review period, the pharmaceutical company may begin Phase 1 clinical trials using 
human subjects. At this stage, a several month study of 20-100 volunteers will test 
dosing rates and patient side effects. If the clinical trial proves successful, the data 
is sent to CDER for analysis and approval (US Dept of Health and Human Services, 
2017). Approximately 70% of drugs will successfully complete this phase (US 
Food & Drug Administration, 2020). Drugs will then move to Phase 2 clinical trials 
where several hundred volunteers will be tested for up to two years to determine 
drug efficacy and patient side effects. The results will then be forwarded to CDER 
and approximately 33% of drugs will successfully complete this phase (US Food & 
Drug Administration, 2020). If approved, drugs will then move to Phase 3 clinical 
trials where up to several thousand volunteers will be tested for 1-4 years on 
efficacy and adverse reactions with approximately 25%-30% of drugs moving to 
Phase 4. At this stage only 17% of drugs are approved for use (Harper, 2020).  
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This process can take an average of 15 years and cost upwards of $2 billion (Divon, 
2015). 
Following approval, drugs enter a post-marketing phase meaning that they are 
available for use. These drugs are monitored and can either be administratively or 
voluntarily withdrawn from the market. An administrative withdrawal is typically 
made within a 1-6 year period following its entrance into the market (Onakpoya et 
al., 2016). Drugs can also be voluntarily withdrawn from the market by the 
manufacturer. One such example was Merck and Co.’s anti-inflammatory drug 
Vioxx which was later found to increase the risk of heart attack and stroke  
(Sibbald, 2004). 
This post-marketing review of adverse drug reactions is then collected via 
MedWatch and made available to manufacturers and researchers alike. 
Identifying Drug Interactions 
 
When clinical healthcare professionals are confronted with identifying interactions 
from multiple medications, they will generally consult drug interaction references 
to look for any known interaction potential. The Nursing Drug Handbook or online 
references such as Micromedex and LexiComp can provide useful information for 
known drug interactions. However, no reference can account for all interactions nor 
estimate the likelihood of an adverse event occurring (Kheshti et al., 2016). 
Adverse Drug Event Severity Assessment 
 
In order to assess the impact severity of adverse drug events on patient health, 
several scales have been developed. The first is a categorization section in 
MedWatch where reporters can document patient outcome by selecting 




Figure 1: MedWatch FDA Form 3500 Patient Outcomes 
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While useful for reporting ADEs, it is important to note that these categories lack 
explanatory descriptions and must be interpreted by the reporter whom may not be 
a medical professional. This could lead to some confusion especially with how to 
interpret other serious or what constitutes life-threatening. 
Modified Hartwig-Siegel 
The scale used in FAERS reporting is a derivative of the Modified HartwigSiegel 
severity scale that categorizes adverse drug reactions into seven levels (Hartwig et 
al., 1992). 
• Level 1: An ADE occurred but required no change in treatment with the 
suspected drug. 
• Level 2: The ADE required that treatment with the suspected drug be held, 
discontinued, or otherwise changed. No antidote or other treatment required. No 
increase in LOS (Length of Stay). 
• Level 3:The ADE required that treatment with the suspected drug be held, 
discontinued, or otherwise changed, and/or an antidote or other treatment was 
required. No increase in LOS. 
• Level 4: (A) Any level 3 ADE which increases LOS by at least 1 day, or (B) The 
ADE was the reason for admission. 
• Level 5: Any level 4 ADE which requires intensive medical care. 
• Level 6: The adverse reaction caused permanent harm to the patient. 
• Level 7: The adverse reaction either directly or indirectly led to the death of the 
patient. 
The primary differences between the Modified Hartwig-Siegel and FDA Form 3500 
is the latter de-emphasis of length of stay as a criteria and the absence of an option 
for no change in treatment. 
Hartwig Severity Assessment 
One of the first attempts at quantifying severity is the Hartwig scale that examines 
adverse reactions in five areas with yes/no categories. This tool calculates severity 
as the sum of all yes answers (Hartwig et al., 1991). 
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• A. Increased monitoring needed? YES NO 
• B. Vital signs change? YES NO 
 
• C. Additional lab work ordered? YES NO 
• D. Treatment needed? YES NO 
• E. Increase in LOS? YES NO 
While the Hartwig scale is useful to categorize drug reaction severity, it lacks the 
granularity found in the either the Modified Hartwig-Siegel or MedWatch. 
Sources of ADE Data 
There are several sources of ADE data including medical literature review, the 
Internet and observational reports (Ventola, 2018). Medical literature review 
typically involves text mining of abstracts from sources such as PubMed to identify 
potential interaction signals. Pharmacovigilance systems that use the Internet will 
typically monitor social media or chat forums to mine discussions for relevant drug 
interactions. Observational systems rely on mining reports generated from sources 
such as EHRs or adverse reports submitted to appropriate government agencies. Of 
the later there are three major data sources where adverse event data can be found; 
DAWN, NEDS and FAERS. All are voluntary repositories of data collected within 
the United States. 
The Drug Abuse Warning Network (DAWN) is a large-scale survey of medical 
records used to monitor drug abuse trends nationwide (Joranson et al., 2000). 
DAWN is a type of public health surveillance system to monitor drug-related visits 
to hospital emergency rooms and identify trends. The eligibility criteria to enter 
data in this source is any non-federal US shortstay hospital with at least one 24-
hour emergency department (Substance Abuse and Mental Health Services 
Administration, 2019). While useful for monitoring drug abuse, the DAWN 
network was discontinued in 2011 and its counterpart NEDS contains similar data. 
Both DAWN and NEDS were found to be statistically similar in data composition 
(Sivigny & Caces, 2018). 
NEDS, the National Emergency Department Sample, is a data service from the 
Healthcare Cost and Utilization Project (HCUP), sponsored by the Agency for 
Healthcare Research and Quality (AHRQ), a division of the US Department of 
Health and Human Services. This repository collects data from nearly 31 million 
US emergency room visits annually across 953 hospitals and provides diagnostic 
ICD coding, patient demographics, insurance and patient outcome.  
Although extensive in scope, data records can be sparse. 
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A third major data source of ADE data is FAERS. Since its creation in 1969, this 
repository has undergone several transformations over the years, however, its 
mission remains the same; to voluntarily collect adverse reaction reports for drugs, 
medication errors and medical devices from manufacturers, medical professionals 
and the general public (Toki & Ono, 2018). This massive database is publicly 
available and the ADE component contains nearly 135,000,000 records spread over 
seven tables from 2004 to 2018 Quarter 2 on adverse events, product complaints, 
and medication error reports. Manufacturers, consumers, and health care 
professionals submit voluntary reports of adverse drug interactions to the FDA. 
MedWatch then collects patient demographic data, the adverse event’s impact on 
patient health (e.g., disability, hospitalization, life-threatening condition or death), 
product availability, suspected products or devices and information about the 
reporter. Because of the lack of training and the variety of reporters contributing to 
FAERS, many database fields contain a non-trivial amount of non-standardized 
data (Veronon et al., 2020). 
Using FAERS Data 
There are several studies that use FAERS data to identify adverse reactions from 
the combination of two drugs. One such study focused on data mining FAERS to 
detect a statistical association between two drugs and found that reporting odds ratio 
provided better signal detection of an adverse event than proportional reporting 
ratio, information component and empirical Bayes geometric mean (Sakaeda et al., 
2013). A second study mined interactions between two drugs using logistic 
regression and found 85% precision and 80% accuracy in predicting that an adverse 
event would not occur (Ibrahim et al., 2016). 
In a bid to apply pharmacovigilance to FAERS data, several notable systems have 
been developed. One system manually curated the adverse effects of cardiovascular 
medicines using FAERS and MEDLINE (Xu & Wang, 2014). In this study drug-
disease pairs were identified by semantic markers such as <drug> CAUSE <side 
effect> or <drug> TREAT <disease> from MEDLINE and compared to adverse 
effects data in FAERS. This combined method found marginally better precision 
and recall than FAERS alone, however, nearly 90% of the data was sacrificed to 
achieve the higher accuracy. 
The largest obstacle to using FAERS data is data integrity, requiring cleaning. Some 
of the common problems involve drug misspellings/abbreviations (Xu & Wang, 
2014), duplicate, missing and non-standardized data (Banda et al., 2016), drug trade 
names vs generics (Sakaeda et al., 2013), making the use of FAERS particularly 
difficult (Saragdhar et al., 2016). 
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Because of the dirty data problem in FAERS, there are companies that offer paid 
services for curated ADE data such as Advera Health Analytics2, DrugLogic3 and 
FDAble4. In addition to paid services there are also several freely available tools: 
AERSMine, AEOLUS and OpenVigil FDA. 
AERSMine 
AERSMine is an ontological tool that normalizes FAERS data and aggregates drugs 
and indications (Saragdhar et al., 2016). It allows researchers to search and 
categorize patients based on demographics, indications, drugs and drug classes as 
well as use exclusion filters. While a useful graphical tool to identify patient groups 
based on apriori knowledge, the drawback is that it does not consider multiple drug 
interactions. Further, the system is limited in the scope of drugs to search. For 
example, the antiviral drug lopinavir only exists in conjunction with ritonavir and 
cannot be queried separately. 
AEOLUS 
AEOLUS (Adverse Event Open Learning through Universal Standardization) is 
another open-source FAERS data source that cleans raw FAERS by imputing 
missing values, removing duplicate records, standardizing drug names against 
OHDSI and reactions/indications against MedDRA for a standard vocabulary 
(Banda et al., 2016). AEOLUS also does not evaluate multiple drug interactions. 
This system reports 95% cleaning of drug-related data. 
OpenVigil FDA 
OpenVigil FDA is an online pharmacovigilance tool that interfaces with the 
OpenFDA website and allows for easier navigation and analysis (Böhm et al., 
2016). This tool also allows for the analysis of adverse effects between two drugs. 
While not entirely clear on the data cleaning aspects, OpenVigil FDA reports 88.1% 
cleaning of drug-related data. Like AERSMine, OpenVigil FDA also relies on 
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The drawbacks to AERSMine, AEOLUS, OpenVigil FDA and other systems are 
that they either limit themselves to curated drugs or at most the interaction between 
two drugs. A more powerful system that can investigate multiple drug combinations 
as well as data related to patient demographics could be a useful tool to researchers. 
SARS-CoV-2 Drugs Under Investigation 
To find safe and effective treatments for SARS-CoV-2, the FDA has streamlined 
the clinical investigation process to speed drug research and test for possible 
treatment options. Drugs with antiviral properties as well as immunotherapy drugs 
are currently under investigation. As of this writing, the NIH is currently providing 
the following covid-19 treatment guidelines (National Institutes of Health, 2020). 
They are not FDA approved at this time. 
Antimalarials 
• Hydroxychloroquine/chloroquine: Insufficient clinical data to 
recommend for or against 
Antiviral Nucleotide Analog 
• Remdesivir: Insufficient clinical data to recommend for or 
against 
Combination Treatment Antimalarial/Antibiotic 
• Hydroxychloroquine/azithromycin: Recommends Against 
Combination Treatment Antivirals HIV Drugs 
• Lopinavir/ritonavir: Recommends Against 
Host Modifiers/Immune-Based Therapy 
 
• Interleukin-6 Inhibitors (sarilumab, siltuximab, tocilizumab): 
Insufficient clinical data to recommend for or against 
• Interleukin-1 Inhibitors (anakinra): Insufficient clinical data to 
recommend for or against 
• Interferons: Recommends Against 
• Janus Kinase Inhibitors: Recommends Against 
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Some combinations such as hydroxychloroquine/azithromycin are recommended 
against because of drug safety issues rather than efficacy. If combinations of drugs 
could be investigated to determine historical adverse reaction severity, clinical trials 
could then focus on testing efficacy for those with lesser adverse drug reactions. 
This will hopefully lead to effective treatment sooner. 
Research Gaps 
From our analysis of the literature, the following gaps in research emerge. First, the 
process of identifying multiple drug interactions either relies on known interactions 
that are documented in interaction handbooks, or rely on datasets that require a 
significant investment in cleaning. Our first challenge is to develop such a system 
that can produce meaningful, clean data. 
Second, we didn’t find any system that focused on the patient severity risk from 
multiple drug interactions. Our second challenge is to incorporate historical data of 
adverse reaction severity for drugs. 
Third, we did not find any systems that examined the interactions of covid-19 drugs 
under investigation by the NIH. 
Our aim is to build a system to produce clean data, that incorporates historical 
patient severity measures from adverse drug interactions, and to study those 
interactions for specific covid-19 drug combinations. Our focus is to address patient 
safety and in turn prioritize clinical research to determine efficacy. 
RESEARCH QUESTIONS 
To address these gaps in the literature we plan to answer the following research 
questions. 
1. What is the adverse drug reaction safety for antiviral drug combinations? 
 
We plan to investigate covid-19 drug combinations such as 
hydroxychloroquine/chloroquine, hydroxychloroquine/azithromycin and 
lopinavir/ritonavir with a focus on patient demographics and symptom frequency. 
Answering this question will help address whether certain patient demographics 
respond to antiviral combinations better than others. 
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2 What is the adverse drug reaction safety for interleukin drug 
combinations? 
 
Applying the same framework to interleukin inhibitors of anakinra, 
sarilumab, siltuximab and tocilizumab; what drug combinations are 
safer than others? 
 
3 What is the adverse drug reaction safety for drug combinations of three 
 covid-19 drugs? 
 
Exploring different combinations might yield interesting results not previously 
explored. 
SYSTEM DESIGN 
To answer these research questions we constructed the Tyler Adverse Drug Event 
System (TylerADE) as shown in Figure 2. 
 
 
Figure 2: TylerADE System 
The TylerADE System is composed of several important areas that crossreference 
multiple external data sources. The first step is to download and ETL the FAERS 
data including legacy AERS data, to TylerADE. 
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Drugs → Drugs Cleaning 
Once the ETL process has completed, the drug data needs to pass through a series 
of automated cleaning steps before it is ready for use.  
This stage standardizes the data by converting all drug names to uppercase, 
removing punctuation/spaces, acronym expansion, correlating drug name 
information against Drugs@FDA and Micromedex Solutions (databases of current 
drug names), and then removing drugs that are vague or lightly used in the corpus. 
The steps are listed below. 
1. Capitalize all drug names 
2. Remove all leading and trailing whitespace, newline and tab characters,  leading 
numbers, special characters and null values 
 
3. Expand all drug name abbreviations (e.g.; VIT B12 → VITAMIN B12) 
4. Partition individual records with multiple drug names into separate records 
5. Cross-reference each drug name against Drugs@FDA 
6. For drugs not found in (5) convert the drug name to its generic form using 
 Micromedex Solutions (Truven Health Analytics, 2017) 
7. Remove records with vague drug names (e.g.; painkiller, multivitamin) 
8. Remove records of any drug that appears less than 30 times 
Performing these steps resulted in a cleaning of 98.3% of the drugs data which 
exceeds the published results of other open-source systems. 
Reactions → Symptom Extraction 
Patient symptom data from the Reactions table is cleaned in a similar manner. 
Symptoms are made uniform through capitalization, removal of 
whitespace/extraneous characters, spellchecked, and aggregated for similar 
symptoms (e.g.; respiratory arrest and respiratory failure). 
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Demographics → Demo. Cleaning 
Demographic cleaning involves data conversions and omitting values for a minority 
of data from FAERS. 
1. Convert age to years 
2. Omit age data for ages less than 0 or greater than 120 
3. Convert gender codes other than Male or Female to Other 
Outcomes → Reaction Severity 
Reaction severity scores are recorded in the Outcomes table as 7 - death, 6 - life-
threatening, 5 - hospitalization, 4 - other serious, 3 - required intervention, 2 - 
disability or permanent damage, and 1 - congenital anomaly. 
 
EXPERIMENTAL DESIGN 
For our experiment we used FAERS data from 2004 Quarter 1 through 2018 
Quarter 2. This data encompasses a total of 135,276,263 records across 7 tables. A 
breakdown of FAERS data is shown in Table 1. 
 
Table 1: FAERS Data by Table (2004Q1 - 2018Q2) 
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Indications are the diagnoses such as rheumatoid arthritis, multiple sclerosis and 
hypertension. Reactions are the observed symptoms such as nausea, death or 
fatigue. Drugs are the drug names and other vital information linked to the ADE. 
As shown by the number of records in the table, ADEs typically involve multiple 
drugs, from a minimum of 1 to a maximum of 152. In looking further at ADEs with 
the potential of multiple drug events, there are 8,552,410 records in which two or 
more drugs were reported. 
In terms of cleaned demographic data and gender, 6,129,171 ADE records were 
female (55.2%), 3,891,117 males (35.1%) and 1,074,279 were other (9.7%).  
In terms of ADEs by age ranges, Table 2 shows that most ADEs occurred for 
patients between 50 and 64 years and that the elderly had the highest proportion of 
reported death from ADEs. 
From this data we plan to test those drug combinations under investigation for 
covid-19 treatment. In particular, how safe are these various drug combinations for 
differing patient demographics. Using the cleaned data from the TylerADE system, 
we will perform a data-driven analysis to evaluate patient reaction severity. 
EXPERIMENTAL RESULTS AND DISCUSSION 
To evaluate the benefits of a data-driven approach to determine drug combination 
safety, we will examine several antiviral covid-19 treatments in cluding 
hydroxychloroquine/azithromycin, hydroxychloroquine/chloroquine and 
lopinavir/ritonavir before using our technique on interleukin inhibitors anakinra, 
sarilumab, siltuximab and tocilizumab, to identify the most promising combinations 
for further clinical study from a drug safety perspective. 
Table 2: ADEs by Age Groups 
Age Group Number ADEs %Death 
Toddlers [0-4] 577,800 15.8% 
Children [5-12] 96,920 7.3% 
Teens [13-19] 163,223 8.3% 
Early Adults [20-34] 557,838 8.8% 
Mid-Adults [35-49] 930,981 9.8% 
Late Adults [50-64] 1,608,995 11.1% 
Retired Adults [65-79] 1,526,699 14.2% 
Elderly [80+] 546,757 19.6% 
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Research Question 1: What is the adverse drug reaction safety for antiviral drug 
combinations 
To answer this we investigate the antiviral drug combinations of 
hydroxychloriquine/azithromycin, hydroxychloriquine/chloriquine, and 
lopinavir/ritonavir. 
Hydroxychloroquine and Azithromycin 
Using the cleaned data in TylerADE, we analyzed the reaction severity of 
hydroxychloroquine/azithromycin by performing a count of adverse reaction 
outcome categories as shown in Table 3. 
 
Table 3: Hydroxychloroquine and Azithromycin Reaction Severity 
  Reaction Outcome Severity Categories 
Drug 1 2 3 4 5 6 7 
Hydroxychloroquine 284 1,831 231 26,964 15,424 1,536 2,747 
Azithromycin 659 1,787 387 18,809 17,901 2,436 3,960 
Together 0 21 1 257 169 9 29 
 
Hydroxychloroquine and azithromycin both had a similar number of adverse drug 
events, 49,017 and 45,939 respectively, whereas their combination only occurred 
486 times. Examining their distributions, hydroxychloroquine versus the 
combination showed statistical difference in reaction severity (χ2 =43.2, df =6, 
p−value = 1.06E−07). Azithromycin versus the combination showed statistical 
equivalence (χ2 =8.7, df =6, p − value = 0.192), meaning that azithromycin had a 
similar reaction severity profile as the combination. This is notable because 
azithromycin has 45,939 adverse drug event records and 45,453 records without 
hydroxychloroquine. Whereas hydroxychloroquine has similar numbers of records 
and does not share the same reaction severity profile as the combination. This likely 
indicates that azithromycin is the primary driver of adverse reactions in the 
combination. 
Focusing further, hydroxychloroquine had an average reaction severity of 4.45, 
azithromycin 4.63 and taken together 4.48. Recall that a reaction severity of 4 
represents other serious and 5 is hospitalization. From a drug safety perspective, 
hydroxychloroquine is involved in less severe adverse drug reactions than either 
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azithromycin or the combination which lends support to NIH guidelines to not 
recommend this combination for covid-19 treatment. 
However, other patient-related characteristics could be a factor to explore. To do 
this we partitioned reaction severity outcomes of the combination of 
hydroxychloroquine and azithromycin by patient age and gender as shown in Table 
4. 
 
Table 4: Hydroxychloroquine and Azithromycin by Demographic 
Demographic n x¯ 
Toddlers [0-4] 21 4.52 
Children [5-12] 2 4.50 
Teens [13-19] 3 4.00 
Early Adults [20-34] 34 4.62 
Mid-Adults [35-49] 84 4.40 
Late Adults [50-64] 158 4.46 
Retired Adults [65-79] 75 4.60 
Elderly [80+] 4 4.50 
Male 106 4.62 
Female 369 4.44 
Other 11 4.09 
 
From this data we noticed reaction severity was fairly uniform across age. It was 
interesting to note the average reaction severity for retired adults and elderly was 
4.60 and 4.50 respectively, indicating that patients receiving 
hydroxychloroquine/azithromycin and had an adverse reaction required more 
extensive medical care. This finding is also remarkable because it is absent the 
influence of covid-19 which is also known to lengthen hospital stays. Given what 
we know about covid-19 and its increased fatality rates for the elderly, the 
combination hydroxychloroquine/azithromycin marginally increases risk for older 
populations. 
Examining differences of gender, we found that males had a higher reaction severity 
to the drug combination (4.62) versus females (4.44) with differences that were 
statistically different (χ2 =13.5, df = 6, p−value = 0.0362). This result is also in line 
with observations that covid-19 infections disproportionately affect male patients. 
Recommending a drug combination with known higher adverse reaction severity 
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for males already disproportionately affected by covid-19 would only exacerbate 
the problem. 
We further examined the top ten patient symptoms by reaction severity for 
hydroxychloroquine/azithromycin as shown in Table 5. Only symptoms with ten or 
more cases are shown to reduce noise from seldom seen symptoms. 
Table 5: Hydroxychloroquine and Azithromycin by Symptoms 
Symptom n x¯ 
Respiratory Failure 17 5.71 
Cardiac Arrest 18 5.61 
Septic Shock 14 5.57 
Fluid Overload 14 5.36 
Hypotension 19 5.32 
Tachycardia 16 5.25 
Type 2 Diabetes Mellitus 12 5.25 
Gastric Bypass 11 5.18 
Sepsis 12 5.08 
Retching 11 5.00 
 
From this data we found that respiratory failure, cardiac arrest and septic shock 
were the three most severe adverse reactions (5.71, 5.61 and 5.57 respectively). 
Recall that 5 represents hospitalization and 6 is life-threatening. Symptoms also 
appear to cluster around cardiopulmonary, toxicity or gastrointestinal. 
Looking at the symptom data for patients 65 years and older, the most severe (5 or 
higher) and frequent (n ≥ 3) adverse reaction outcomes were associated with abasia, 
abdominal pain upper, anaemia, atrial fibrillation, blood glucose increased, bone 
pain, chest discomfort, coagulopathy, constipation, gastrointestinal haemorrhage, 
haemoptysis, haemorrhagic anaemia, heart rate increased, hyperhidrosis, malaise, 
melaena, renal failure and shock haemorrhagic. Given the NIH’s recommendation 
against using the combination of hydroxychloroquine/azithromycin because of 
toxicity and negative clinical results, the adverse symptom data would concur with 
the toxicity assessment. 
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Hydroxychloroquine and Chloroquine 
We further examine the reaction severity outcomes of the drug combination 
hydroxychloroquine/chloroquine as shown in Table 6. 
 
Table 6: Hydroxychloroquine and Chloroquine Reaction Severity 
  Reaction Outcome Severity Categories 
Drug 1 2 3 4 5 6 7 
Hydroxychloroquine 284 1,831 231 26,964 15,424 1,536 2,747 
Chloroquine 4 72 22 1,238 1,089 108 330 
Together 0 7 3 122 92 7 30 
 




Table 7: Hydroxychloroquine and Chloroquine by Demographic 
 
Demographic n x¯ 
Toddlers [0-4] 16 4.81 
Children [5-12] 0 – 
Teens [13-19] 0 – 
Early Adults [20-34] 19 4.37 
Mid-Adults [35-49] 60 4.63 
Late Adults [50-64] 99 4.81 
Retired Adults [65-79] 19 4.39 
Elderly [80+] 6 5.33 
Male 54 4.61 
Female 204 4.67 
Other 5 5.80 
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From the age data there were zero reported adverse events for children [5-12] and 
teens [13-19]. The data did exhibit increasing reaction severity as it relates to age. 
The reaction severity for elderly was much higher (5.33) indicating that patients 
with adverse reactions generally required more extensive medical care. 
Examining differences in gender, we found that females had a higher reaction 
severity to the drug combination (4.67) versus males (4.61), however the 
differences were found to be statistically equivalent (χ2 = 10.2, df = 6, p − value = 
0.118). Unlike the prior combination, hydroxychloroquine with chloroquine 
showed no reaction severity differences by gender. 
Looking at patient symptoms, we listed the top ten by reaction severity as shown in 
Table 8. Only symptoms with ten or more cases are shown to reduce noise from 
seldom seen symptoms. 
 
Table 8: Hydroxychloroquine and Chloroquine by Symptoms 
 
Symptom n x¯ 
Overdose 13 5.92 
Cardiac Arrest 20 5.85 
Hypokalaemia 11 5.82 
Respiratory Failure 14 5.43 
Myocardial Infarction 10 5.00 
Cardiomyopathy 14 4.86 
Cardiac Failure Congestive 12 4.75 
Pneumonia 33 4.70 
Muscular Weakness 11 4.64 
Atrioventricular Block Complete 10 4.60 
 
From this table we found that overdose, cardiac arrest and hypokalaemia were the 
three most severe adverse reactions from the drug combination (5.92, 5.85 and 5.82 
respectively). Symptoms appear to be mostly cardiopulmonary. 
Given the NIH’s neutral stance on the combination of 
hydroxychloroquine/chloroquine, the adverse event data would suggest that this 
combination poses an increased risk versus hydroxychloroquine/azithromycin. This 
risk is observed in a higher incidence of drug interaction severity among elderly 
populations and symptoms of mostly a cardiac nature. We would recommend a 
review of clinical study data to verify these results. 
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Lopinavir and Ritonavir 
Performing the same analysis for the drug combination lopinavir/ritonavir 
we performed a count of adverse reaction outcome categories as shown in 
Table 9. 
 
Table 9: Lopinavir and Ritonavir Reaction Severity 
 Reaction Outcome Severity Categories 
Drug 1 2 3 4 5 6 7 
Lopinavir 1,919 674 232 7,678 6,689 1,205 2,272 
Ritonavir 3,996 1,872 455 26,059 21,964 3,506 6,372 
Together 1,910 665 230 7,521 6,587 1,198 2,233 
 
Lopinavir had 20,669 adverse reaction events, ritonavir 64,224 and their 
combination occurred 20,344 times. Examining their distributions, lopinavir versus 
the combination showed statistical equivalence in reaction severity (χ2 = 0.3, df = 6, 
p − value = 0.999) and showed significant overlap indicating that lopinavir and 
ritonavir are commonly seen together in the data. Ritonavir versus the combination 
showed statistical difference in reaction severity (χ2 = 350.1, df = 6, p − value = 
1.505E −72). Focusing further, lopinavir had an average reaction severity of 4.42, 
ritonavir 4.50 and taken together 4.41. Extracting adverse drug events for lopinavir 
that does not include ritonavir, lopinavir’s adverse severity was 4.57, considerably 
higher than the combination 4.41. Ritonavir exclusive of lopinavir was 4.54. This 
was an interesting finding as both drugs taken together had a lower adverse reaction 
severity than exclusive of each other. 
We further examine other patient-related characteristics of age and gender as shown 
in Table 10. 
From the data, the drug combination disproportionately affects children [5-12] and 
those 35 and older. However, the elderly were most impacted (5.15). 
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Table 10: Lopinavir and Ritonavir by Demographic 
Demographic n x¯ 
Toddlers [0-4] 2,365 3.71 
Children [5-12] 164 4.64 
Teens [13-19] 249 4.44 
Early Adults [20-34] 2,898 4.36 
Mid-Adults [35-49] 4,647 4.74 
Late Adults [50-64] 2,306 4.77 
Retired Adults [65-79] 478 4.87 
Elderly [80+] 13 5.15 
Male 11,264 4.59 
Female 6,918 4.33 
Other 2,214 3.78 
 
Examining differences of gender, we found that males had a higher reaction severity 
to the drug combination (4.59) versus females (4.33) with differences that were 
statistically significant (χ2 =2,680.0, df = 6, p − value ≈ 0). 
We further examined the top ten patient symptoms by reaction severity for 
lopinavir/ritonavir as shown in Table 11. Only symptoms with ten or more cases 
are shown to reduce noise from seldom seen symptoms. 
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Table 11: Lopinavir and Ritonavir by Symptoms 
Symptom n x¯ 
Suicide 20 6.85 
Death Neonatal 72 6.19 
Vomiting Projectile 10 6.10 
Oxygen Consumption Decreased 14 6.00 
Enterococcal Infection 12 6.00 
Bladder Distension 10 6.00 
Metastatic Neoplasm 10 6.00 
Aspiration 17 5.94 
Cardiac Arrest 10 5.90 
Sudden Cardiac Death 18 5.89 
 
From this data we found that suicide, neonatal death and projectile vomit were the 
three most severe adverse reactions (6.85, 6.19 and 6.10 respectively). Recall that 
6 represents life-threatening and 7 is death. Symptoms appear to vary and are not 
restricted to limited groupings. 
Looking at symptom data for patients 65 years and older, the most severe (5.5 or 
higher) and frequent (n≥25) adverse reaction outcomes were associated with bone 
marrow failure, circulatory collapse, hepatic failure, hepatotoxicity, multiple organ 
dysfunction syndrome, pneumonia, pneumonia bacterial and sepsis. It is important 
to note that no symptom was associated with an average adverse reaction severity 
of 6 or higher. This would imply that in spite of the NIH recommendation against 
the combination of lopinavir/ritonavir, from a patient safety perspective (and not 
drug efficacy), perhaps a re-evaluation of this combination for patients 65 years and 
older may be of benefit. 
Answering Research Question 1 
So to answer our first research question of what is the adverse drug reaction safety 
for antiviral drug combinations, our analysis found hydroxychloriquine to cause 
lesser adverse reactions than hydroxychloriquine/azithromycin (4.45 and 4.48 
respectively). The combination was also adversely affecting retired adults and 
males (4.60 and 4.62 respectively).  
For hydroxychloriquine/chloriquine, the combination was more severe at 4.69. This 
combination also adversely affected the elderly and females (5.33 and 4.67 
respectively).  
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However, for early adults and retired adults the reaction severity was much less 
(4.37 and 4.39 respectively). For lopinavir/ritonavir the combination had an adverse 
severity of 4.41. This combination also adversely affected the elderly (5.15) and 
males (4.59). However, for toddlers the reaction severity is considerably less (3.71). 
To further investigate, we analyze reaction severity by age grouping for 
hydroxychloroquine/azithromycin, hydroxychloroquine/chloroquine and 
lopinavir/ritonavir as shown in Figure 3. 
Baseline represents all adverse drug events in the cleaned FAERS database and 
we use it for comparison to several drug combinations; 
hydroxychloroquine/azithromycin (H+A), hydroxychloroquine/chloroquine 
(H+C) and lopinavir/ritonavir 
(L+R). From this figure, the elderly [80+] are disproportionately affected more by 
hydroxychloroquine/chloroquine (5.33) and lopinavir/ritonavir (5.15) versus the 
baseline of all drugs (5.00). The interesting combination is 
hydroxychloroquine/azithromycin that has dramatically lower reaction severity for 
this population (4.50). The other combination to note is lopinavir/ritonavir for 
Toddlers [0-4] that has a reduced reaction severity of 3.71. 
 
 
Figure 3: Reaction Severity by Age Grouping 
The NIH currently recommends against hydroxychloriquine/azithromycin, is 
neutral towards hydroxychloriquine/chloriquine, and recommends against 
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lopinavir/ritonavir. From our analysis of patient safety at the macro-level, all three 
combinations pose risk (4.48, 4.69 and 4.41 respectively). However, from the 
perspective of different age groups and genders, we observed a variety of reaction 
severity outcomes with some posing much lower reaction severity. Perhaps further 
study could determine if the benefits of these combinations can outweigh the risks 
for specific patient populations. 
Research Question 2: What is the adverse drug reaction safety for interleukin 
drug combinations? 
Using the cleaned data from TylerADE, we analyzed the reaction severity of 
interleukins: anakinra, sarilumab, siltuximab and tocilizumab. We then performed 
a count of adverse reaction outcome categories as shown in Table 12. 
From the data, sarilumab and siltuximab had the fewest adverse reaction records of 
18 and 38 respectively, whereas anakinra and tocilizumab had 3,680 and 34,793 
respectively. Analyzing each combination for reaction severity is shown in Table 
13. 
 
Table 12: Interleukin Reaction Severity Counts 
 Reaction Outcome Severity Categories 
Drug 1 2 3 4 5 6 7 
Anakinra 21 87 12 1,589 1,314 255 402 
Sarilumab 0 3 0 13 2 0 0 
Siltuximab 0 0 0 17 10 6 5 
Tocilizumab 47 955 15 18,160 11,527 1,667 2,422 
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Table 13: Interleukin Reaction Severity Averages 
 
 
From this data, sarilumab had the lowest reaction severity of 3.78 versus siltuximab 
at 4.97. There were no observations of anakinra/siltuximab or sarilumab/siltuximab 
in the data. It was further worth noting that interleukin combinations containing 
sarilumab had lower reaction severity. For our chisquared analysis we compared 
the individual drugs against each other. From a drug safety perspective it would 
appear that sarilumab is the safest of the four, however, we also recognize the 
limited adverse reaction data and would suggest clinical study to verify these 
results. 
Given the prevalence of the combination of anakinra and tocilizumab, we further 
examine other patient-related characteristics of age and gender as shown in Table 
14. 
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Table 14: Anakinra and Tocilizumab by Demographic 
Demographic n x¯ 
Toddlers [0-4] 61 4.75 
Children [5-12] 76 4.92 
Teens [13-19] 17 4.71 
Early Adults [20-34] 31 4.65 
Mid-Adults [35-49] 97 4.25 
Late Adults [50-64] 172 4.48 
Retired Adults [65-79] 46 4.24 
Elderly [80+] 3 4.67 
Male 332 4.85 
Female 513 4.35 
Other 53 4.85 
 
From the data, the drug combination disproportionately affects toddlers [0-4], 
children [5-12] and teens [13-19]. However, early adults [20-34] and elderly [80+] 
were also observed to be adversely affected. Patients with ages between 35 and 79 
appeared the least impacted. 
Examining differences of gender, we found that males had a higher reaction severity 
to the drug combination (4.85) versus females (4.35) with differences that were 
statistically significant (χ2 = 164.0, df = 6, p − value = 8.27E −33). 
We further examined the top ten patient symptoms by reaction severity for 
anakinra/tocilizumab as shown in Table 15. Only symptoms with ten or more cases 
are shown to reduce noise from seldom seen symptoms. 
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Table 15: Anakinra and Tocilizumab by Symptoms 
Symptom n x¯ 
Respiratory Failure 12 6.08 
Activated Partial Thromboplastin Time Prolonged 11 5.45 
Blood Fibrinogen Decreased 11 5.45 
Blood Pressure Inadequately Controlled 11 5.45 
International Normalised Ratio Increased 11 5.45 
Pleural Effusion 12 5.42 
Serum Ferritin Increased 13 5.38 
Pneumocystis Jirovecii Pneumonia 21 5.29 
Lung Infection 12 5.25 
Infection 10 5.20 
 
 
From this data we found that pulmonary-related symptoms were the most severe 
adverse reactions. Anakinra and tocilizumab are both immunotherapy drugs and are 
most commonly used for the treatment of rheumatoid arthritis via inflammation 
reduction. 
It is interesting that this drug combination would affect the lungs rather than cause 
typical immunosuppressant problems such as diabetes, fatigue, neurological 
impairment and gastrointestinal issues. Regardless of the source of these symptom 
changes, in the context of a potential therapy for covid-19 patients, using a drug 
combination with the added potential for pulmonaryrelated adverse reactions might 
be problematic.  
Research Question 3: What is the adverse drug reaction safety for drug 
combinations of three covid-19 drugs? 
To answer Research Question 3 we investigated every 3 drug combination of 
antivirals and interleukins we previously studied. Many of these combinations, 
especially between antivirals and interleukins, lack guidance from the NIH for their 
use as covid-19 treatments. Using a data-driven approach we hope to uncover new 
potential treatments that are relatively low in adverse reaction severity. 
Table 16 demonstrates reaction severity outcomes for three covid-19 drug 
combinations (n ≥ 10) of antivirals and interleukins. For many combinations we 
observed zero entries. This absence of adverse reactions is likely due to sparse 
prescriptions of the combination rather than a panacea. 
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Table 16: Three Drug Combination Reaction Severity 
Drug Combination n x¯ 
Azithromycin, Hydroxychloroquine and Tocilizumab 14 4.21 
Azithromycin, Lopinavir and Ritonavir 1,066 4.91 
Chloroquine, Hydroxychloroquine and Tocilizumab 20 4.95 
Hydroxychloroquine, Lopinavir and Ritonavir 17 4.65 
 
We call attention to the combination of azithromycin, hydroxychloroquine and 
tocilizumab (4.21). This three drug combination has lower adverse reaction severity 
than any of its components as shown in Table 17. The next lowest adverse reaction 
severity is that of hydroxychloroquine/tocilizumab (4.24), and interestingly 
enough, neither this nor the three drug combination has guidance from the NIH as 
a potential covid-19 treatment. 
 
Table 17: Three Drug Combination Reaction Severity 
Drug Combination n x¯ 
Azithromycin, Hydroxychloroquine, Tocilizumab 14 4.21 
Azithromycin, Hydroxychloroquine 486 4.48 
Azithromycin, Tocilizumab 88 4.78 
Hydroxychloroquine, Tocilizumab 5,494 4.24 
Azithromycin 45,939 4.63 
Hydroxychloroquine 49,017 4.45 
Tocilizumab 34,793 4.58 
 
We also examined patient-related characteristics of age and gender as shown in 
Table 18. 
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Table 18: Azithromycin, Hydroxychloroquine and Tocilizumab by 
Demographic 
Demographic n x¯ 
Toddlers [0-4] 0 – 
Children [5-12] 0 – 
Teens [13-19] 0 – 
Early Adults [20-34] 2 4.50 
Mid-Adults [35-49] 6 4.17 
Late Adults [50-64] 1 4.00 
Retired Adults [65-79] 1 4.00 
Elderly [80+] 0 – 
Male 4 4.25 
Female 10 4.20 
Other 0 – 
 
From this data, the combination of azithromycin, hydroxychloroquine and 
tocilizumab had adverse reactions observed in patients between 20 and 79 years of 
age. Of the 14 adverse reactions observed, 11 were categorized as other serious and 
3 were hospitalization. Males were also observed to have higher adverse reactions 
(4.25) than females (4.20). 
From a drug safety perspective, the three drug combination of azithromycin, 
hydroxychloroquine and tocilizumab appears to have decreased reaction severity 
and should be evaluated in a clinical trial as a potential covid-19 treatment. 
 
CONCLUSIONS, LIMITATIONS AND FUTURE DIRECTIONS 
We employed a data-driven approach to determine covid-19 drug combination 
safety using a cleaned version of FDA FAERS data in TylerADE. We found that 
the combination hydroxychloroquine/azithromycin had an average adverse reaction 
severity of 4.48 for all populations reporting an adverse drug reaction. We further 
found males more impacted and drug event severity marginally increased with 
patient age. When compared against the other drug combinations, 
hydroxychloroquine/azithromycin has the least adverse reactions severity on 
elderly [80+] populations (4.50).  
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The drug combination of hydroxychloroquine/chloroquine had an average adverse 
reaction severity of 4.69 for all populations and no differences between gender. 
However, elderly [80+] patients were disproportionately affected with an average 
adverse reaction severity of 5.33. The drug combination of lopinavir/ritonavir had 
an average adverse reaction severity of 4.41 for all populations and also 
disproportionately affected males (4.59) and the elderly [80+] (5.15). It was also 
interesting to note that lopinavir/ritonavir had the least adverse reaction on toddlers 
[0-4] (3.71). For the interleukins, sarilumab when used in combination 
demonstrated lower adverse reaction severity than other interleukin drugs in 
combination. Finally, we found that the combination of azithromycin, 
hydroxychloroquine and tocilizumab had low adverse reaction severity (4.21) and 
from a drug safety perspective shows potential as a covid19 treatment option. 
There are several limitations to this study. First, this study relies on adverse drug 
event reports reported to the FDA. We recognize that not all adverse drug events 
will be reported or there could be a skew towards reporting only the most severe 
adverse events. To accommodate this we only made comparisons within the 
datasets between drugs. Second, we rely on the reported data to be accurate and 
complete. We employed a painstaking process of data cleaning to ensure the 
reliability of data and omitted it when necessary. Third, although there are large 
numbers of adverse drug events on total, some drug combinations have few records 
and made comparison difficult. We did include the number of records in these 
situations so that readers can make an informed decision. Fourth, the purpose of 
this study is to evaluate drug combination safety from historical records. It is meant 
as a prelude to clinical trial data. Drug efficacy is not considered. Fifth, dosing, 
manufacturer and route of administered drugs was not considered. 
Only the presence/absence of the drug was evaluated. While we recognize their 
importance, we felt partitioning to this level of detail would dilute the data to be of 
little comparative value and felt it best for clinical trial data to address those 
concerns. 
Future directions include investigating the safety of other drug combinations that 
show promise such as other antivirals and interleukins. Further partitioning of data 
based on patient ethnicity or pre-existing conditions might also prove insightful. 
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